Cargando…
Oxidative Stress in Schizophrenia
Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131721/ https://www.ncbi.nlm.nih.gov/pubmed/22131939 http://dx.doi.org/10.2174/157015911795596595 |
_version_ | 1782207750515720192 |
---|---|
author | Bošković, Marija Vovk, Tomaž Kores Plesničar, Blanka Grabnar, Iztok |
author_facet | Bošković, Marija Vovk, Tomaž Kores Plesničar, Blanka Grabnar, Iztok |
author_sort | Bošković, Marija |
collection | PubMed |
description | Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia. |
format | Online Article Text |
id | pubmed-3131721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Bentham Science Publishers Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31317212011-12-01 Oxidative Stress in Schizophrenia Bošković, Marija Vovk, Tomaž Kores Plesničar, Blanka Grabnar, Iztok Curr Neuropharmacol Article Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia. Bentham Science Publishers Ltd 2011-06 /pmc/articles/PMC3131721/ /pubmed/22131939 http://dx.doi.org/10.2174/157015911795596595 Text en ©2011 Bentham Science Publishers Ltd http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Bošković, Marija Vovk, Tomaž Kores Plesničar, Blanka Grabnar, Iztok Oxidative Stress in Schizophrenia |
title | Oxidative Stress in Schizophrenia |
title_full | Oxidative Stress in Schizophrenia |
title_fullStr | Oxidative Stress in Schizophrenia |
title_full_unstemmed | Oxidative Stress in Schizophrenia |
title_short | Oxidative Stress in Schizophrenia |
title_sort | oxidative stress in schizophrenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131721/ https://www.ncbi.nlm.nih.gov/pubmed/22131939 http://dx.doi.org/10.2174/157015911795596595 |
work_keys_str_mv | AT boskovicmarija oxidativestressinschizophrenia AT vovktomaz oxidativestressinschizophrenia AT koresplesnicarblanka oxidativestressinschizophrenia AT grabnariztok oxidativestressinschizophrenia |